Analysts Set Agenus Inc. (NASDAQ:AGEN) PT at $31.00

Shares of Agenus Inc. (NASDAQ:AGEN) have been given an average rating of “Hold” by the six brokerages that are covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $10.50.

A number of research firms have issued reports on AGEN. HC Wainwright downgraded Agenus from a “buy” rating to a “neutral” rating and cut their price target for the company from $40.00 to $9.00 in a research note on Thursday, July 18th. Jefferies Financial Group reaffirmed a “hold” rating and set a $7.00 target price (up from $3.00) on shares of Agenus in a research report on Friday, July 19th. StockNews.com lowered shares of Agenus from a “hold” rating to a “sell” rating in a research note on Monday, August 12th. B. Riley lowered their price target on shares of Agenus from $42.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday, August 14th. Finally, Robert W. Baird lowered Agenus from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $35.00 to $8.00 in a report on Friday, July 19th.

Institutional Trading of Agenus

Several hedge funds and other institutional investors have recently modified their holdings of AGEN. Vanguard Group Inc. boosted its holdings in Agenus by 13.7% in the 1st quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company’s stock worth $19,953,000 after buying an additional 4,134,232 shares during the period. Acadian Asset Management LLC lifted its position in shares of Agenus by 1,959.9% during the first quarter. Acadian Asset Management LLC now owns 757,397 shares of the biotechnology company’s stock worth $439,000 after acquiring an additional 720,629 shares in the last quarter. Pennant Investors LP purchased a new stake in shares of Agenus during the fourth quarter worth $389,000. Virtu Financial LLC bought a new position in shares of Agenus in the fourth quarter worth $213,000. Finally, Readystate Asset Management LP boosted its stake in Agenus by 14.3% in the 4th quarter. Readystate Asset Management LP now owns 2,016,783 shares of the biotechnology company’s stock worth $1,670,000 after purchasing an additional 252,124 shares during the period. Institutional investors own 61.46% of the company’s stock.

Agenus Trading Down 3.6 %

NASDAQ AGEN opened at $5.09 on Tuesday. The company has a market cap of $106.88 million, a P/E ratio of -0.40 and a beta of 1.33. The company has a fifty day simple moving average of $10.89 and a 200 day simple moving average of $11.71. Agenus has a 12-month low of $4.41 and a 12-month high of $31.20.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($2.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.33) by ($1.19). The firm had revenue of $23.51 million for the quarter, compared to analysts’ expectations of $64.73 million. During the same period in the prior year, the company earned ($4.00) EPS. Sell-side analysts predict that Agenus will post -10.73 EPS for the current year.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.